在加拿大环境下，注射毒品使用与 HIV 抗逆转录病毒治疗中断。
Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting.
机构信息
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
出版信息
AIDS Behav. 2013 Jan;17(1):68-73. doi: 10.1007/s10461-012-0136-y.
Abstract
We investigated whether drug-related behaviors predicted antiretroviral therapy (ART) discontinuation among a cohort of injection drug users (IDU) in a Canadian setting. Cox regression analyses were used to investigate the impact of drug use patterns on rates of ART discontinuation among a sample of HIV-positive IDU in Vancouver, Canada between May 1996 and April 2008. In total, 408 HIV-positive IDU initiated ART during the study period, among whom 257 (63.0%) discontinued ART at least once. Rates of ART discontinuation were not significantly elevated among those who reported ongoing injection of heroin, cocaine, or other illicit drugs in comparison to those who reported not injecting drugs. However, public drug use was significantly predictive of ART discontinuation. Our findings may contribute to a reconsideration of the role of active drug use in determining retention in ART programs among IDU.
摘要
我们研究了在加拿大的一个注射吸毒者（IDU）队列中，与药物相关的行为是否会预测抗逆转录病毒治疗（ART）的中断。使用 Cox 回归分析来研究在 1996 年 5 月至 2008 年 4 月期间，加拿大温哥华的一组 HIV 阳性 IDU 中，药物使用模式对 ART 中断率的影响。在研究期间，共有 408 名 HIV 阳性 IDU 开始接受 ART，其中 257 名（63.0%）至少中断过一次 ART。与未注射毒品的人相比，报告持续注射海洛因、可卡因或其他非法药物的人中断 ART 的比率并没有显著升高。然而，公开的药物使用是 ART 中断的显著预测因素。我们的研究结果可能有助于重新考虑在 IDU 中，积极的药物使用在确定抗逆转录病毒治疗方案的保留率方面的作用。
相似文献
1
Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting.
AIDS Behav. 2013 Jan;17(1):68-73. doi: 10.1007/s10461-012-0136-y.
2
Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
AIDS Care. 2011 Aug;23(8):980-7. doi: 10.1080/09540121.2010.543882.
3
Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study.
HIV Med. 2015 Mar;16(3):137-51. doi: 10.1111/hiv.12184. Epub 2014 Aug 15.
4
Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment.
AIDS Behav. 2013 Jan;17(1):168-73. doi: 10.1007/s10461-012-0319-6.
5
Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users.
AIDS Behav. 2014 Apr;18(4):740-6. doi: 10.1007/s10461-013-0584-z.
6
Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.
Drug Alcohol Depend. 2012 Jul 1;124(1-2):108-12. doi: 10.1016/j.drugalcdep.2011.12.019. Epub 2012 Jan 14.
7
Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.
AIDS Care. 2014 Apr;26(4):459-65. doi: 10.1080/09540121.2013.832724. Epub 2013 Sep 9.
8
Suboptimal plasma HIV-1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: an observational cohort study.
Sex Transm Infect. 2014 Aug;90(5):418-22. doi: 10.1136/sextrans-2013-051408. Epub 2014 Feb 12.
9
Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
Antivir Ther. 2019;24(1):19-25. doi: 10.3851/IMP3265.
10
The feasibility of an intensive case management program for injection drug users on antiretroviral therapy in St. Petersburg, Russia.
Harm Reduct J. 2013 Sep 5;10:15. doi: 10.1186/1477-7517-10-15.
引用本文的文献
1
AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.
Infection. 2024 Apr;52(2):637-648. doi: 10.1007/s15010-024-02188-y. Epub 2024 Feb 21.
2
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286).
Patient Prefer Adherence. 2022 Dec 13;16:3267-3281. doi: 10.2147/PPA.S379065. eCollection 2022.
3
Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review.
BMJ Open. 2021 Sep 23;11(9):e047511. doi: 10.1136/bmjopen-2020-047511.
4
Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011-2017.
AIDS Res Ther. 2021 Jan 9;18(1):4. doi: 10.1186/s12981-020-00328-6.
5
Healthcare Effectiveness Data and Information Set (HEDIS) measures of alcohol and drug treatment initiation and engagement among people living with the human immunodeficiency virus (HIV) and patients without an HIV diagnosis.
Subst Abus. 2019;40(3):302-310. doi: 10.1080/08897077.2019.1580239. Epub 2019 Mar 25.
6
Physicians' patient base composition and mortality among people living with HIV who initiated antiretroviral therapy in a universal care setting.
BMJ Open. 2019 Mar 20;9(3):e023957. doi: 10.1136/bmjopen-2018-023957.
7
Mortality and virological failure among HIV-infected people who inject drugs on antiretroviral treatment in China: An observational cohort study.
Drug Alcohol Depend. 2017 Jan 1;170:189-197. doi: 10.1016/j.drugalcdep.2016.11.011. Epub 2016 Nov 19.
8
Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative.
AIDS Behav. 2017 Feb;21(2):402-409. doi: 10.1007/s10461-016-1470-2.
9
Public health and international drug policy.
Lancet. 2016 Apr 2;387(10026):1427-1480. doi: 10.1016/S0140-6736(16)00619-X. Epub 2016 Mar 24.
10
Antiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era.
Open Forum Infect Dis. 2014 Jun 19;1(1):ofu010. doi: 10.1093/ofid/ofu010. eCollection 2014 Mar.
本文引用的文献
1
Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence.
AIDS Care. 2010 Mar;22(3):397. doi: 10.1080/09540120903193757.
2
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1(Suppl 1):S22-32. doi: 10.1097/QAI.0b013e318209751e.
3
Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis.
Lancet Infect Dis. 2010 Jul;10(7):464-9. doi: 10.1016/S1473-3099(10)70097-9.
4
Enhanced HIV testing, treatment, and support for HIV-infected substance users.
JAMA. 2010 Apr 14;303(14):1423-4. doi: 10.1001/jama.2010.421.
5
Assisted injection in outdoor venues: an observational study of risks and implications for service delivery and harm reduction programming.
Harm Reduct J. 2010 Mar 19;7:6. doi: 10.1186/1477-7517-7-6.
6
'Seek, test and treat' slows HIV.
Nature. 2010 Feb 25;463(7284):1006. doi: 10.1038/4631006a.
7
Disparity in health care: HIV, stigma, and marginalization in Nepal.
J Int AIDS Soc. 2009 Aug 26;12:16. doi: 10.1186/1758-2652-12-16.
8
Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review.
Addiction. 2008 Aug;103(8):1242-57. doi: 10.1111/j.1360-0443.2008.02269.x.
9
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review.
Lancet. 2008 Nov 15;372(9651):1733-45. doi: 10.1016/S0140-6736(08)61311-2. Epub 2008 Sep 23.
10
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England.
BMC Infect Dis. 2008 Sep 18;8:120. doi: 10.1186/1471-2334-8-120.
Zotero 插件